Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach.

Fecha de publicación: 01/01/2021 Fecha Ahead of Print: 31/08/2020

Autores de IIS La Fe

• Raquel López Reyes

  Autor

• Grace Jacqueline Oscullo Yépez

  Autor

• Alberto García Ortega

  Autor

Participantes ajenos a IIS La Fe

• Jiménez D
• Cano I

Grupos

• Neumología

  

  Leader

  Miguel Ángel Martínez García

Abstract

The new SARS-CoV-2 coronavirus has created an unprecedented global health problem, resulting in more than 250,000 confirmed deaths. The disease produced by this virus, called Covid-19, presents with variable clinical manifestations, from practically asymptomatic patients with catarrhal processes to severe pneumonias that rapidly evolve to acute respiratory distress syndrome (ARDS) and multiorgan failure. In recent weeks, papers have been published describing coagulation disorders and arterial and venous thrombotic complications in these patients, mainly among those admitted to intensive care units. The infection triggers an immune response, which causes different inflammatory mediators to be released into the blood. These include cytokines, which interact with platelets and different coagulation proteins, and promote thrombogenesis. One of the most widely studied coagulation markers in Covid-19 is D-dimer (DD), raised levels of which have prognostic implications, although the best cut-off point for the diagnosis of venous thromboembolism (VTE) in this population has not been clarified, nor has its usefulness in determining the intensity of thromboprophylaxis required in these patients. Until sufficiently robust information (preferably from well-designed clinical trials) is available, the recommendations of clinical practice guidelines for the prophylaxis, diagnosis and treatment of VTE should be followed in Covid-19 patients.

Keywords

• Anticoagulation, COVID-19, Covid-19, Pulmonary embolism, Thrombosis